Observational AVODART (Dutasteride) Study In Benign Prostatic Hyperplasia Subjects - OASIS

GlaxoSmithKline173 enrolled

Overview

This study was designed to assess the effectiveness of dutasteride in the actual clinical practice of prostate assessment clinics in the UK in accordance with best practice over a 12-month period.

Study Type

OBSERVATIONAL

Enrollment

173

Conditions

Prostatic Hyperplasia

Interventions

IPSS QuestionnairePROCEDURE

EQ-5D QuestionnairePROCEDURE

Eligibility

Sex: MALE

Medical Language ↔ Plain English

Inclusion Criteria: * Patients who not have received any pharmacological treatment or surgical interventions for BPH (Benign Prostatic Hyperplasia). * Patients should be prescribed dutasteride in compliance with the UK SmPC and BAUS guidelines on the treatment of BPH. * Patients must only enter the study after the decision to prescribe dutasteride has been undertaken. Exclusion criteria: None specified

Locations (27)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.